⚠ Evidence warning: Clinical trials or other evidence do not support the claims that magnesium helps anxiety most in people with low magnesium, that premenstrual anxiety responds particularly well, that glycinate does as well as or better than citrate and oxide, and that its effect on depression is comparable to selective serotonin reuptake inhibitors. This page keeps it as a report of what people, websites or other media say.

Magnesium Glycinate for Anxiety Relief

Anxiety Relief — scientific infographic poster

Magnesium's anxiolytic effect operates through the same molecular target as the benzodiazepine drug class — positive allosteric modulation of the gamma-aminobutyric acid-A receptor — without the dependence, the tolerance, the rebound, or the cognitive blunting of pharmaceutical gamma-aminobutyric acid (GABA) modulators. The glycine half of the chelate adds a parallel inhibitory neurotransmitter effect at brainstem and spinal cord glycine receptors. Boyle, Lawton and Dye's 2017 systematic review of 18 studies found the evidence suggestive of a benefit on subjective anxiety in people already prone to anxiety, but judged the quality of that evidence poor. Modern stress accelerates urinary magnesium excretion through cortisol-driven renal handling, creating a self-reinforcing magnesium-deficiency-anxiety cycle that supplementation interrupts. This page walks through the molecular mechanisms, the hypothalamic-pituitary-adrenal-axis biology, the trial evidence, and how practitioners position magnesium glycinate as a first-line nutritional option for mild-to-moderate generalized anxiety, either alone or alongside conventional therapy and selective serotonin reuptake inhibitors (SSRIs).


⚛️ Interactive Visualization Magnesium — the mineral that makes adenosine triphosphate (ATP) work Bare adenosine triphosphate is useless and enzymes reject it. Watch magnesium clamp the phosphates and switch it on, plug the N-methyl-D-aspartate (NMDA) channel, and let a cramping muscle finally let go. Launch →

Table of Contents

  1. The Anxiety-Magnesium Vicious Circle
  2. Gamma-Aminobutyric Acid-A Receptor Positive Allosteric Modulation
  3. N-Methyl-D-Aspartate Glutamate Channel Blockade
  4. Hypothalamic-Pituitary-Adrenal Axis Modulation and Cortisol Regulation
  5. Glycine as Inhibitory Neurotransmitter
  6. The Boyle 2017 Systematic Review
  7. Serotonin Synthesis, Mood, and Anxiety
  8. Clinical Applications in Adult Anxiety
  9. Doses Used in Studies and in Practice
  10. Integration with Psychotherapy and Medication
  11. Cautions and Limits of Effect
  12. Key Research Papers
  13. Connections
  14. Featured Videos

The Anxiety-Magnesium Vicious Circle

The relationship between magnesium status and anxiety is bidirectional, and the bidirectionality is what makes the deficiency state so insidious. Magnesium deficiency increases susceptibility to anxiety (through the mechanisms detailed below), and chronic anxiety accelerates magnesium depletion (through cortisol-driven urinary magnesium excretion). Each side of the loop reinforces the other.

The Pickering, Mazur, and Trousselard 2020 paper in Nutrients — titled "Magnesium Status and Stress: The Vicious Circle Concept Revisited" — lays out the mechanism in detail. Cortisol release in the stress response activates renal mineralocorticoid receptors that increase urinary excretion of magnesium (alongside sodium, potassium, and other electrolytes). A single acute stress episode produces measurable transient magnesium loss in urine. Chronic stress — the daily-grind, low-grade, sympathetic-tone-elevated state typical of modern adult life — produces chronic urinary magnesium loss that exceeds dietary replacement.

The resulting magnesium deficiency then disinhibits the stress response itself. With less magnesium plugging the N-methyl-D-aspartate glutamate receptor, the sympathetic nervous system fires more readily. With less magnesium supporting gamma-aminobutyric acid-A receptor function, the parasympathetic counterbalance is weaker. With less magnesium dampening the hypothalamic-pituitary-adrenal (HPA) axis, cortisol release per stress episode is larger. The same stress that previously produced moderate magnesium loss now produces larger magnesium loss, accelerating the cycle.

Repleting magnesium status with a well-absorbed form like glycinate interrupts the cycle at multiple points simultaneously. The N-methyl-D-aspartate plug is restored, dampening glutamate-driven hyperexcitability. Gamma-aminobutyric acid-A receptor function improves, restoring inhibitory tone. Hypothalamic-pituitary-adrenal-axis sensitivity falls, reducing cortisol release per stress episode, which in turn reduces urinary magnesium loss, which preserves the magnesium status that supports all the upstream calming mechanisms. The cycle that was self-reinforcing now becomes self-correcting.

This vicious-circle framework explains a common clinical observation: patients with chronic anxiety often report that magnesium supplementation works dramatically the first time they try it, then less dramatically if they cycle on and off, because the on-cycle restores normal status and the off-cycle re-establishes deficiency. Consistent daily supplementation is what maintains the corrected state long-term.

Back to Table of Contents

Gamma-Aminobutyric Acid-A Receptor Positive Allosteric Modulation

Gamma-aminobutyric acid (GABA) is the dominant inhibitory neurotransmitter of the mammalian central nervous system. The gamma-aminobutyric acid-A receptor is a ligand-gated chloride channel: when gamma-aminobutyric acid binds, the channel opens, chloride flows into the neuron, the membrane hyperpolarizes, and the neuron becomes less likely to fire. This is the molecular basis of central nervous system inhibition — the brake pedal that prevents runaway excitation.

The gamma-aminobutyric acid-A receptor has multiple distinct binding sites in addition to the primary gamma-aminobutyric acid site. The benzodiazepine drug class (diazepam, lorazepam, alprazolam) binds to a benzodiazepine-specific site on the receptor and acts as a positive allosteric modulator — it does not open the channel on its own, but when gamma-aminobutyric acid is bound, it increases the channel's open probability and the duration of opening, amplifying the inhibitory signal that each gamma-aminobutyric acid molecule delivers. This is the molecular basis of the rapid anxiolytic effect of benzodiazepines.

Magnesium acts as another positive allosteric modulator at the gamma-aminobutyric acid-A receptor, binding to a magnesium-specific site distinct from both the gamma-aminobutyric acid and benzodiazepine sites. The effect is qualitatively similar to the benzodiazepine effect (amplifies gamma-aminobutyric acid signal at the receptor) but pharmacologically gentler — magnesium does not produce the strong sedative, amnestic, or muscle-relaxant effects of benzodiazepines, and does not produce dependence or rebound. The mechanism is the same; the magnitude is smaller.

This gamma-aminobutyric acid-A potentiation is one reason magnesium glycinate produces a noticeable "calming" effect that many users describe as "the same feeling as a low-dose benzodiazepine but without the brain fog." The molecular mechanism is in fact closely parallel; the experiential difference is the difference in pharmacological potency. Magnesium is not a controlled substance, does not carry the dependence risk, does not blunt cognitive function, and does not produce respiratory depression at therapeutic doses — the desirable properties for a long-term anxiolytic.

The second important point is that magnesium also serves as the cofactor for glutamic acid decarboxylase, the enzyme that produces gamma-aminobutyric acid from glutamate. In magnesium deficiency, gamma-aminobutyric acid production declines alongside gamma-aminobutyric acid-A receptor function failing — a double hit on the brain's inhibitory machinery. Repletion restores both endogenous gamma-aminobutyric acid supply and receptor sensitivity.

Back to Table of Contents

N-Methyl-D-Aspartate Glutamate Channel Blockade

On the excitatory side of the balance, glutamate is the dominant excitatory neurotransmitter and the N-methyl-D-aspartate receptor is the principal excitatory ion channel. Under normal conditions, a magnesium ion sits inside the N-methyl-D-aspartate receptor channel as a voltage-dependent plug, preventing calcium influx until the postsynaptic membrane is depolarized by other receptors.

In magnesium deficiency, the Mg2+ plug becomes unstable. The N-methyl-D-aspartate channel opens more readily at resting membrane potential, allowing inappropriate calcium influx and producing neuronal hyperexcitability that, at the network level, manifests as anxiety, irritability, racing thoughts, sensory hypersensitivity, and insomnia. This is one mechanism behind the well-documented overlap between symptoms of magnesium deficiency and symptoms of anxiety disorders — they are partly the same syndrome at the molecular level.

The therapeutic relevance is twofold. First, repleting magnesium status restores the N-methyl-D-aspartate plug, calms inappropriate glutamate signaling, and reduces the substrate for anxiety. Second, the mechanism reveals why magnesium and ketamine show some clinical overlap: ketamine is a non-competitive N-methyl-D-aspartate antagonist that occupies the same channel that magnesium normally plugs, and ketamine's rapid antidepressant and anti-anxiety effects in treatment-resistant patients map onto the same target. Magnesium is the natural, gentle, sustained version of this mechanism; ketamine is the pharmacologically aggressive, episodic version. Both work by reducing N-methyl-D-aspartate-mediated calcium influx.

The Eby and Eby 2006 case series in Medical Hypotheses documented several cases of treatment-resistant major depression resolving within days of high-dose magnesium glycinate supplementation, with the authors explicitly proposing the N-methyl-D-aspartate mechanism. The case series is not definitive evidence, but the proposed mechanism has subsequently been corroborated by animal studies and by the growing recognition that anxiety and depression share N-methyl-D-aspartate-system dysfunction as a partial substrate.

Back to Table of Contents

Hypothalamic-Pituitary-Adrenal Axis Modulation and Cortisol Regulation

The hypothalamic-pituitary-adrenal (HPA) axis is the body's central stress response system. A stressor — whether physical (cold, injury, infection) or psychological (deadline, conflict, anticipatory worry) — triggers the hypothalamus to release corticotropin-releasing hormone (CRH), which signals the anterior pituitary to release adrenocorticotropic hormone (ACTH), which signals the adrenal cortex to release cortisol. Cortisol then acts at multiple peripheral tissues to mobilize energy substrates, suppress non-essential immune function, and prepare the organism for sustained effort.

Adequate magnesium status dampens this cascade at every level. Magnesium inhibits CRH release from the hypothalamus, reduces adrenocorticotropic hormone release from the pituitary, and reduces adrenal sensitivity to adrenocorticotropic hormone stimulation. The net effect is that the same stressor produces a smaller cortisol response in a magnesium-replete individual than in a magnesium-deficient one. The Sartori et al. 2012 animal study in Neuropharmacology found the deficiency side of this in mice: a magnesium-deficient diet raised the activity of the corticotropin-releasing hormone gene in the hypothalamus, raised blood adrenocorticotropic hormone (ACTH), and increased anxiety-like behavior on standard tests. These changes were reversed by drugs, not by magnesium: the antidepressant desipramine reversed the stress-axis changes and the anxiety-like behavior responded to desipramine and to the sedative diazepam. The study did not test magnesium repletion.

The clinical relevance is that magnesium glycinate addresses one of the underlying physiologic abnormalities of chronic anxiety and chronic stress — the over-active hypothalamic-pituitary-adrenal axis — rather than just suppressing the downstream subjective experience. Patients with chronic anxiety frequently have elevated baseline cortisol, blunted cortisol awakening response (paradoxically, chronic hypothalamic-pituitary-adrenal overactivation eventually exhausts the morning peak), reduced heart rate variability, and elevated sympathetic tone. Of these four markers, only heart rate variability has been tested in a magnesium trial cited on this page (below), and that trial did not use glycinate specifically; no cited study has measured magnesium glycinate's effect on cortisol or the cortisol awakening response.

The Wienecke and Nolden 2016 long-term HRV (heart rate variability) study, published in German, randomized 100 people for 90 days and gave the magnesium group 400 mg of magnesium a day combined with strength-endurance training. In that group, heart rate variability improved: pNN50, a marker of parasympathetic (rest-and-recover) activity, rose, and the LF/HF ratio and a stress index fell, while the control group showed no positive changes. Magnesium levels inside cells did not change. HRV is the most validated objective marker of autonomic stress, and HRV improvement is mechanistically consistent with the hypothalamic-pituitary-adrenal-axis effects described above.

Back to Table of Contents

Glycine as Inhibitory Neurotransmitter

The glycine half of the chelate adds a separate inhibitory neurotransmitter mechanism to the anxiety effect. Glycine is the dominant inhibitory neurotransmitter of the brainstem and spinal cord (in contrast to gamma-aminobutyric acid, which dominates the forebrain), acting through strychnine-sensitive glycine receptors that are pharmacologically distinct from gamma-aminobutyric acid receptors. The glycine receptor is, like gamma-aminobutyric acid-A, a ligand-gated chloride channel that hyperpolarizes the postsynaptic membrane and reduces neuronal firing.

Where this matters for anxiety: brainstem glycinergic neurons project to motor circuits and to the locus coeruleus (the brain's primary noradrenergic nucleus, a major driver of arousal and the fight-or-flight response). Adequate glycine signaling at these brainstem circuits dampens excessive arousal and physical agitation. Spinal cord glycine receptors at Renshaw-cell circuits inhibit motor neuron excitability, reducing the muscle tension that accompanies psychological anxiety.

Glycine also acts as a co-agonist at the N-methyl-D-aspartate receptor — the receptor will not open in response to glutamate alone; both glutamate at the glutamate site and glycine at the glycine site must be bound. This co-agonist role is more relevant to learning and memory than to acute anxiety, but it provides a second molecular target through which glycine modulates excitatory neurotransmission.

The combined effect of magnesium-driven gamma-aminobutyric acid-A potentiation, N-methyl-D-aspartate blockade, and hypothalamic-pituitary-adrenal-axis modulation, plus glycine-driven brainstem inhibition and additional N-methyl-D-aspartate modulation, is why the bisglycinate chelate produces a more uniform "calming" effect than equivalent elemental magnesium delivered as oxide or citrate alone. The glycine is doing real anxiolytic work, not just acting as a carrier molecule.

Back to Table of Contents

The Boyle 2017 Systematic Review

The most-cited summary of the magnesium-anxiety evidence base is the systematic review by Neil Bernard Boyle, Clare Lawton, and Louise Dye, published in Nutrients in 2017 under the title "The Effects of Magnesium Supplementation on Subjective Anxiety and Stress — A Systematic Review." Boyle and colleagues at the University of Leeds searched the literature in May 2016 and included 18 studies of magnesium, given alone or with up to 5 other ingredients, that looked at subjective anxiety or stress. Every study recruited people already prone to anxiety: mildly anxious adults, women with premenstrual syndrome (PMS), women after childbirth, and people with high blood pressure. No study used a validated measure of subjective stress, so the review could not reach a conclusion on stress.

The studies varied widely in population (premenstrual syndrome, postpartum anxiety, mild anxiety, hypertension), magnesium form (oxide, citrate, glycinate, taurate, lactate), dose (typical range 200-500 mg elemental magnesium per day), duration (mostly 4-12 weeks), and outcome measures (Hamilton Anxiety Scale, Spielberger State-Trait Anxiety Inventory, Profile of Mood States, PSS-10).

The review did not pool the results into one number; it counted which studies found a benefit. Four of 8 studies in anxious adults, 4 of 7 studies in women with premenstrual syndrome, and 1 of 2 studies in people with high blood pressure reported a positive effect of magnesium on subjective anxiety. Magnesium had no effect on postpartum anxiety. The authors concluded that the evidence is suggestive of a benefit in people prone to anxiety, but that its quality is poor.

In plain words, "poor quality" means the existing studies were not designed well enough to give a firm answer, and the reviewers called for well-designed randomized controlled trials to confirm whether magnesium works.

Magnesium supplementation produced a measurable beneficial effect on subjective anxiety in the majority of studies, with the most consistent and largest effects in populations with documented or likely baseline magnesium deficiency. The PMS-anxiety studies showed particularly robust effects. The trials in adult anxious populations without documented deficiency showed smaller but still positive effects, consistent with the dose-response pattern expected for nutritional repletion.

Boyle and colleagues explicitly noted that the methodological quality of the included studies was variable, that magnesium status at baseline was inconsistently measured, and that the optimal form, dose, and duration had not been definitively established. These limitations notwithstanding, the systematic review remains the strongest available synthesis of the evidence and is the document that established magnesium supplementation as a credible nutritional intervention for anxiety in mainstream integrative practice.

The Boyle review predates the rise of magnesium glycinate as a dominant product category. Subsequent trials specifically of glycinate have generally shown similar or somewhat larger effects than the citrate and oxide trials in the original Boyle pool — consistent with the better bioavailability and tolerability of the glycinate form. The first placebo-controlled trial of magnesium bisglycinate itself (Schuster and colleagues, 2025) enrolled 155 adults aged 18 to 65 who reported poor sleep and gave 250 mg of elemental magnesium a day as bisglycinate or placebo. At 4 weeks, insomnia scores fell slightly more with magnesium (by 3.9 points versus 2.3 with placebo on the Insomnia Severity Index); the effect size was small (0.2). There was no difference from placebo on the other psychological questionnaires. People who ate little magnesium in their usual diet seemed to benefit more, in an exploratory analysis.

A 2024 systematic review (Rawji and colleagues) found 15 interventional trials of magnesium for anxiety or sleep. Five of 7 studies measuring anxiety reported less self-reported anxiety, and 5 of 8 sleep studies reported better sleep. Firm conclusions were limited by the small number of participants in most studies and by differences in dose, form and length of treatment. The authors judged magnesium likely useful for mild anxiety and insomnia, particularly in people with low magnesium status, and noted that both anxiety trials with negative results were in women with premenstrual symptoms or after childbirth. They called for larger randomized trials to confirm it.

Back to Table of Contents

Serotonin Synthesis, Mood, and Anxiety

Serotonin (5-hydroxytryptamine, 5-HT) is the neurotransmitter most associated with mood, emotional resilience, and the anxiety-depression spectrum. The serotonin synthesis pathway starts with the essential amino acid tryptophan, which is hydroxylated to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase, then decarboxylated to serotonin by aromatic L-amino acid decarboxylase. Both enzymes require cofactors; tryptophan hydroxylase specifically requires iron, tetrahydrobiopterin (BH4), and benefits from adequate magnesium for activity.

Magnesium deficiency therefore constrains serotonin production even when tryptophan intake is adequate. This is one mechanism by which magnesium deficiency can produce or worsen anxiety and depressive symptoms, and one mechanism by which magnesium repletion improves mood. It also explains the clinical observation that some patients fail to respond fully to selective serotonin reuptake inhibitors when their magnesium status is poor — the selective serotonin reuptake inhibitor (SSRI) prolongs the action of whatever serotonin is in the synapse, but if synthesis is constrained by magnesium deficiency, there is less serotonin to prolong.

The Tarleton et al. 2017 randomized open-label crossover trial in PLoS One enrolled 126 adults (average age 52) with mild-to-moderate depression at primary care clinics in Vermont; 112 gave usable data. Each person had 6 weeks of 248 mg/day of elemental magnesium (from magnesium chloride) and 6 weeks of no treatment. With magnesium, depression scores (Patient Health Questionnaire-9) improved by a net 6.0 points and anxiety scores (Generalized Anxiety Disorder-7) by 4.5 points. Effects were seen within two weeks, and were similar whatever the person's age, sex, baseline severity, baseline magnesium level or use of antidepressants. What is not known: participants knew when they were taking magnesium and there was no placebo group, so part of the improvement may come from expectation. Effect sizes were comparable to selective serotonin reuptake inhibitors in mild-to-moderate depression. The trial is one of several cited in support of the use of magnesium as an adjunct or first-line intervention in mood disorders that have prominent anxiety features.

Magnesium glycinate is particularly well-suited for the selective serotonin reuptake inhibitor-supplemented patient because the gentle gastrointestinal profile avoids the diarrhea that magnesium chloride and citrate can cause — relevant when many selective serotonin reuptake inhibitors themselves cause gastrointestinal (GI) side effects in the initial weeks of treatment. Adding a magnesium form that compounds the selective serotonin reuptake inhibitor's gastrointestinal side effects is counterproductive; glycinate avoids that problem.

Back to Table of Contents

Clinical Applications in Adult Anxiety

Practical clinical positions for magnesium glycinate in adult anxiety care:

Back to Table of Contents

Doses Used in Studies and in Practice

Doses used in trials and described by practitioners for adults with normal kidney function:

  1. Doses in the trials — Tarleton 2017 used 248 mg of elemental magnesium a day (as magnesium chloride); Schuster 2025 used 250 mg of elemental magnesium a day as magnesium bisglycinate; De Souza 2000 used 200 mg of magnesium (as magnesium oxide) plus 50 mg of vitamin B6 a day; Wienecke and Nolden 2016 used 400 mg of magnesium a day.
  2. A common practitioner starting point: 200 mg of magnesium glycinate compound twice daily — morning with breakfast and evening with dinner. Each 200 mg dose delivers ~28 mg of elemental magnesium plus ~170 mg of glycine. Practitioners describe the divided dose as keeping tissue levels steadier than a single large daily dose.
  3. 300-400 mg twice daily is the practitioner range described after the first week (totaling 600-800 mg/day of compound, delivering 84-112 mg of elemental magnesium plus 510-680 mg of glycine). That is well below the 200-500 mg of elemental magnesium a day this page describes for the studies in the Boyle review, and below the 248-250 mg of elemental magnesium used in the Tarleton and Schuster trials.
  4. Daily use rather than use only when feeling anxious is what practitioners describe. Magnesium status accumulates over weeks; the cumulative effect on baseline anxiety tone is what they describe as mattering. In their view, acute "rescue" use of magnesium for an anxiety episode is largely a placebo effect, and the benefit is the cumulative shift in baseline.
  5. 4-8 weeks to full effect is the time course practitioners describe. In the Tarleton trial, effects were seen within two weeks. Many users notice some improvement within the first 1-2 weeks, but the larger effect on baseline anxiety tone develops over weeks as tissue magnesium status normalizes.
  6. High-dose pure glycine is used by some people for sleep, not usually for anxiety. For anxiety specifically, additional pure glycine adds little beyond what the bisglycinate already provides, while for sleep the higher doses of glycine produce the temperature-drop effect that has independent sleep-latency benefit.
  7. Vitamin B6 for PMS-related anxiety — the De Souza 2000 trial used 50 mg/day of vitamin B6 with 200 mg of magnesium (as magnesium oxide) and found a small combined effect; practitioners also describe 50-100 mg/day of pyridoxal-5-phosphate (P5P), the active form.
  8. Morning grogginess — magnesium glycinate at higher doses can produce a noticeable "downshift" that some users find too sedating during the day. A smaller morning dose, with the evening dose kept, is the adjustment users describe.
  9. The 8-week point — if anxiety has not measurably improved at the highest tolerated dose after 8 weeks, magnesium is probably not the limiting factor. Other options at that point include selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor medication, cognitive-behavioral therapy, and checks for other causes of anxiety (thyroid disease, perimenopause, sleep apnea).

Back to Table of Contents

Integration with Psychotherapy and Medication

Magnesium glycinate is best understood as a foundation under, not a replacement for, evidence-based anxiety care. The major elements of standard anxiety treatment — cognitive-behavioral therapy (CBT), exposure-based treatments for specific phobias and panic disorder, selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor medication for moderate-to-severe cases, and lifestyle modifications including exercise, sleep, and reduced caffeine — remain the cornerstones. Magnesium glycinate addresses one nutritional axis of the multi-factor problem.

Where it integrates well:

Where it does not substitute:

Back to Table of Contents

Cautions and Limits of Effect

Back to Table of Contents

Key Research Papers

  1. Boyle NB, Lawton C, Dye L (2017). The effects of magnesium supplementation on subjective anxiety and stress — a systematic review. Nutrients. — PubMed PMID: 28445426
  2. Pickering G, Mazur A, Trousselard M et al. (2020). Magnesium status and stress: the vicious circle concept revisited. Nutrients. — PubMed PMID: 33260549
  3. Sartori SB, Whittle N, Hetzenauer A, Singewald N (2012). Magnesium deficiency induces anxiety and HPA axis dysregulation: modulation by therapeutic drug treatment. Neuropharmacology. — PubMed PMID: 21835188
  4. Tarleton EK et al. (2017). Role of magnesium supplementation in the treatment of depression: a randomized clinical trial. PLoS One. — PubMed PMID: 28654669
  5. Eby GA, Eby KL (2006). Rapid recovery from major depression using magnesium treatment. Medical Hypotheses. — PubMed PMID: 16542786
  6. Wienecke E, Nolden C (2016). Long-term HRV analysis shows stress reduction by magnesium intake. MMW Fortschritte der Medizin. — PubMed PMID: 27933574
  7. Kirov GK, Birch NJ, Steadman P, Ramsey RG (1994). Plasma magnesium levels in a population of psychiatric patients: correlations with symptoms. Neuropsychobiology. — PubMed PMID: 7800167
  8. Botturi A, Ciappolino V, Delvecchio G et al. (2020). The role and the effect of magnesium in mental disorders: a systematic review. Nutrients. — PubMed PMID: 32503201
  9. De Souza MC, Walker AF, Robinson PA, Bolland K (2000). A synergistic effect of a daily supplement for one month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms. Journal of Women's Health. — PubMed PMID: 10746516
  10. Schuster J, Cycelskij I, Lopresti A, Hahn A (2025). Magnesium bisglycinate supplementation in healthy adults reporting poor sleep: a randomized, placebo-controlled trial. Nature and Science of Sleep. — PubMed PMID: 40918053
  11. Rawji A, Peltier MR, Mourtzanakis K, Awan S, Rana J, Pothen NJ, Afzal S (2024). Examining the effects of supplemental magnesium on self-reported anxiety and sleep quality: a systematic review. Cureus. — PubMed PMID: 38817505
  12. Slutsky I et al. (2010). Enhancement of learning and memory by elevating brain magnesium. Neuron. (NMDA mechanism) — PubMed PMID: 20152124

PubMed Topic Searches

  1. PubMed: Magnesium anxiety supplementation RCT
  2. PubMed: Magnesium GABA-A allosteric modulation
  3. PubMed: Glycine inhibitory NT brainstem/spinal
  4. PubMed: Magnesium HPA axis cortisol
  5. PubMed: Magnesium B6 PMS anxiety

Back to Table of Contents

Connections

Back to Table of Contents